In the spotlight
The continued burden of 新型冠状病毒肺炎 for the immunocompromised
新型冠状病毒肺炎
疫苗 and Immune Therapies
Our ambition is to develop and deliver transformative vaccines and antibodies, providing long-lasting immunity to millions of people, where the burden of disease is greatest.
首页 / Our therapy areas / 疫苗 and Immune Therapies
澳门葡京赌博游戏的承诺
We are committed to developing and delivering transformative vaccines and antibodies, providing long-lasting immunity for millions of people, where the burden of disease is greatest. During the 新型冠状病毒肺炎 pandemic, we played an important role as part of a truly global effort to respond to a new and unprecedented challenge.1 We will continue to advance science in vaccines and immune therapies and work with partners to drive improvements in public health and ensure our science reaches millions more people.
Looking to the future
Imagine a world where a single vaccine could protect people against coronavirus, 流感, and respiratory syncytial virus. A world where 长效 antibodies protect the most vulnerable against those same infectious diseases, for more than a year. This is the future we are working towards.
Our focus areas
To achieve our ambition, we are optimising the potential of both vaccines and antibodies to ensure no patient is left behind. We are engineering next generation vaccines that have the potential to generate potent and long-lasting immune responses. At the same time, we are pioneering novel approaches to develop highly targeted, 长效 antibodies, optimised with our half-life extension technology.2 We focus on a range of pathogens, including SARS-CoV-2,3 流感4 和RSV.5
Complementary approach
疫苗 for active immunisation; antibodies for passive immunisation for those who can’t mount an immune response
技术
Innovative next-generation technologies for vaccines; accelerated human antibody discovery, 长效, high-yield manufacturing for antibodies.
病原体
SAR-CoV-2, 流感, RSV & 除了
澳门葡京赌博游戏的承诺 to combatting coronavirus (新型冠状病毒肺炎) disease
We remain committed to discovering and developing new approaches to fight 新型冠状病毒肺炎, with a focus on protecting the most vulnerable patients who remain disproportionally impacted by 新型冠状病毒肺炎 and are at risk of severe disease.
澳门葡京赌博游戏的人民
We are a passionate and dedicated team of scientists, 研究人员, 临床医生, medical and commercial professionals. We are breaking new boundaries with our discoveries, supported by our heritage, and empowered by our collaborations with commercial, academic and 政府ernment leaders across the world.
The 疫苗 and Immune Therapies unit is at the forefront of a new and exciting era of disease prevention. I am inspired by our team’s dedication to pushing the boundaries of science, helping to create a fairer and healthier future for all.
加入澳门葡京赌博游戏
Join and help us develop the next generation of vaccines and highly targeted, 长效 antibodies.
澳门葡京赌博游戏的药品
We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations. 澳门葡京赌博游戏的药品 are approved in individual countries for specific uses and the information we provide for patients is 政府erned by local regulations. 在某些情况下, health care professionals and patients can visit local 澳门葡京网赌游戏 websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
Evusheld
tixagevimab and cilgavimab
Fluenz Tetra/FluMist Quadrivalent
流感 vaccine live, intra-nasal
Synagis
palivizumab
澳门葡京赌博游戏的管道 for V&I
We are passionate about pushing the boundaries of science, developing next generation vaccines and antibodies that have the power to transform the way we prevent and treat endemic and pandemic viruses.
疫苗 & Immune therapies (as of 25 April 2024)
第一阶段
二期
二期
第三阶段
模块项目
模块项目
最新消息
参考文献
1. 澳门葡京网赌游戏. Vaxzevria shown in expert review to provide equally effective protection against 新型冠状病毒肺炎 hospitalisation and death as mRNA vaccines [Last accessed: October 2022]. Available from: http://www.AstraZeneca.com/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19.html.
2. 澳门葡京网赌游戏 news release. 新型冠状病毒肺炎 Long-Acting AntiBody (LAAB) Combination AZD7442 Rapidly Advances into 第三阶段 Clinical Trials.: Last accessed: October 2022. Available from: http://www.AstraZeneca.com/media-centre/press-releases/2020/covid-19-长效-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html.
3. Voysey米 等. Single-dose administration and the in流感ence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397(10277):881–91.
4. ClinicalTrials.政府. Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries (EVOLVE): Last accessed: October 2022. Available from: http://clinicaltrials.政府/ct2/show/NCT05315323.
5. ClinicalTrials.政府. A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants (MELODY) [Last accessed: October 2022]. Available from: http://clinicaltrials.政府/ct2/show/NCT03979313
Veeva ID: Z4-62731
日期 of preparation: March 2024